Healthcare Resource Utilization and Associated Costs in Patients With Transthyretin Cardiac Amyloidosis and Non-amyloid Heart Failure
Author(s)
Justin Grodin, MD, MPH1, Ahmad Masri, MD, MS2, Richard Wright, MD3, Jean-François Tamby, MD, MBA4, Heather Falvey, MSc5, Liana Hennum, MHA4, Margarita Udall, MPH6, Melissa Allison, BS7, Chaitanya Badwe, PhD7, Rakesh Ramesh, BE8, Martin Subash Surya SR, MSc8, Sandesh Dev, MD9, Jose Nativi-Nicolau, MD10;
1University of Texas Southwestern, Dallas, TX, USA, 2Oregon Health and Sciences University, Portland, OR, USA, 3Pacific Heart Institute, Santa Monica, CA, USA, 4BridgeBio Pharma, Inc, San Francisco, CA, USA, 5BridgeBio Pharma Inc., San Francisco, CA, USA, 6BridgeBio Pharma, Inc., San Francisco, CA, USA, 7Definitive Healthcare, New York, NY, USA, 8Definitive Healthcare, Bengaluru, India, 9Arizona State University, Scottsdale, AZ, USA, 10Mayo Clinic, Jacksonville, FL, USA
1University of Texas Southwestern, Dallas, TX, USA, 2Oregon Health and Sciences University, Portland, OR, USA, 3Pacific Heart Institute, Santa Monica, CA, USA, 4BridgeBio Pharma, Inc, San Francisco, CA, USA, 5BridgeBio Pharma Inc., San Francisco, CA, USA, 6BridgeBio Pharma, Inc., San Francisco, CA, USA, 7Definitive Healthcare, New York, NY, USA, 8Definitive Healthcare, Bengaluru, India, 9Arizona State University, Scottsdale, AZ, USA, 10Mayo Clinic, Jacksonville, FL, USA
OBJECTIVES: Transthyretin cardiac amyloidosis (ATTR-CM) is a progressive disease associated with a substantial burden to healthcare systems. This study aimed to describe and compare inpatient length of stay (LOS), days hospitalized, and healthcare costs for ATTR-CM and non-amyloid heart failure (HF) cohorts.
METHODS: Using the Optum Clinformatics Data Mart (January 2016-September 2023), patients with ATTR-CM were identified based on presence of HF and/or cardiomyopathy (CM) occurring within 2 years of first amyloidosis diagnosis (excluding light-chain amyloidosis) and followed for ≥12 months after first HF/CM diagnosis. Patients with ATTR-CM were matched 1:1 to patients with non-amyloid HF using propensity score matching. Cardiovascular-related hospitalizations and associated costs were assessed.
RESULTS: A total of 4571 patients were included in each matched cohort. Of these patients, 3440 (75.3%) with ATTR-CM and 2991 (65.4%) with non-amyloid HF had ≥1 cardiovascular-related hospitalizations during follow-up. The ATTR-CM cohort had more total hospitalizations than the non-amyloid HF cohort (11 170 vs 8085 hospitalizations); 71.5% of the ATTR-CM cohort and 60.8% of the non-amyloid HF cohort experienced >1 hospitalization. Patients with ATTR-CM had a longer LOS per hospitalization (mean=8.03 days) than the non-amyloid HF cohort (mean=7.47 days) (P<0.001). The ATTR-CM cohort (vs non-amyloid HF cohort) had a numerically higher rate of hospitalizations >4 days (75.4% vs 70.5%). Cardiovascular-related hospitalization costs per patient per year (PPPY) (mean) were higher in the ATTR-CM cohort ($46 669) than the non-amyloid HF cohort ($39 253) (P<0.001). The ATTR-CM cohort (vs non-amyloid HF cohort) had a numerically higher rate of cardiovascular-related hospitalization costs PPPY exceeding $20 000 (64.0% vs 54.6%).
CONCLUSIONS: This study suggests that patients with ATTR-CM have more frequent and longer LOS in hospitals compared with those with non-amyloid HF. This results in higher hospitalization costs PPPY for the ATTR-CM cohort, reinforcing the greater burden imposed on patients and the healthcare system
METHODS: Using the Optum Clinformatics Data Mart (January 2016-September 2023), patients with ATTR-CM were identified based on presence of HF and/or cardiomyopathy (CM) occurring within 2 years of first amyloidosis diagnosis (excluding light-chain amyloidosis) and followed for ≥12 months after first HF/CM diagnosis. Patients with ATTR-CM were matched 1:1 to patients with non-amyloid HF using propensity score matching. Cardiovascular-related hospitalizations and associated costs were assessed.
RESULTS: A total of 4571 patients were included in each matched cohort. Of these patients, 3440 (75.3%) with ATTR-CM and 2991 (65.4%) with non-amyloid HF had ≥1 cardiovascular-related hospitalizations during follow-up. The ATTR-CM cohort had more total hospitalizations than the non-amyloid HF cohort (11 170 vs 8085 hospitalizations); 71.5% of the ATTR-CM cohort and 60.8% of the non-amyloid HF cohort experienced >1 hospitalization. Patients with ATTR-CM had a longer LOS per hospitalization (mean=8.03 days) than the non-amyloid HF cohort (mean=7.47 days) (P<0.001). The ATTR-CM cohort (vs non-amyloid HF cohort) had a numerically higher rate of hospitalizations >4 days (75.4% vs 70.5%). Cardiovascular-related hospitalization costs per patient per year (PPPY) (mean) were higher in the ATTR-CM cohort ($46 669) than the non-amyloid HF cohort ($39 253) (P<0.001). The ATTR-CM cohort (vs non-amyloid HF cohort) had a numerically higher rate of cardiovascular-related hospitalization costs PPPY exceeding $20 000 (64.0% vs 54.6%).
CONCLUSIONS: This study suggests that patients with ATTR-CM have more frequent and longer LOS in hospitals compared with those with non-amyloid HF. This results in higher hospitalization costs PPPY for the ATTR-CM cohort, reinforcing the greater burden imposed on patients and the healthcare system
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE378
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Rare & Orphan Diseases